We next examined the cellular effects of treating ARH3 KO cells with temozolomide (TMZ), a methylating agent used clinically to treat glioblastoma and still under study in other solid tumors, including ovarian cancers [58,59]. This evidence concerns the gene ADPRS and ovarian cancer.